Hematologic Toxicity in Lung Cancer

  • Francesc Casas
  • Núria Viñolas
Part of the Medical Radiology Radiation Oncology book series (MEDRAD)


Lung Cancer Clin Oncol Hematologic Toxicity Radiat Oncol Biol Phys Advanced NSCLC 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abrams RA, Lichter AS, Bromer RH et al (1985) The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy. Cancer 55:1429–1435PubMedGoogle Scholar
  2. Adams JR, Lyman GH, Djubegovic B et al (2002) G-CSF as prophylaxis of febrile neutropenia in SCLC. Review of findings from 13 studies of cost-effectiveness, evidence-based guidelines, patterns of care and surveys of ASCO members. Exp Opin Pharmacother 3:1273–1281CrossRefGoogle Scholar
  3. Albers DS, Dorr RT (1998) New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 3:15–34PubMedGoogle Scholar
  4. Antonadou D, Throuvalas N, Petridis A et al (2003) Effect of amifostine on toxicities with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57:402–408CrossRefPubMedGoogle Scholar
  5. Balducci L, Hardy CL (1998) Anemia of aging: a model of erythropoiesis in cancer patients. Cancer Control 19:327–338Google Scholar
  6. Balducci L, Hardy CL, Lyman GH (2000) Hemopoietic reserve in the older cancer patient: clinical and economic considerations. Cancer Control 7:539–547PubMedGoogle Scholar
  7. Baraldi-Junkins CA, Beck AC, Rothstein G (2000) Hematopoiesis and cytokines. Relevance to cancer and aging. Hematol Oncol Clin North Am 14:45–61PubMedGoogle Scholar
  8. Bennett CL, Weeks JA, Somerfield MR et al (1999) Use of hematopoietic colony-stimulating factors: comparison of the 1994 and 1997 American Society of Clinical Oncology surveys regarding ASCO Clinical Practice Guidelines. Health Services Research Committee of the American Society of Clinical Oncology. J Clin Oncol 17:3676–3681PubMedGoogle Scholar
  9. Berghmans T, Paesmans M, Lafitte JJ et al (2002) Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 37:115–123CrossRefPubMedGoogle Scholar
  10. Billingham LJ, Cullen MH (2001) The benefits of chemotherapy in patients subgroup with unresectable non-small-cell lung cancer. Ann Oncol 12:1671–1675CrossRefPubMedGoogle Scholar
  11. Booton R, Jones M, Thatcher N (2003) Lung cancer-7: management of lung cancer in elderly patients. Thorax 58:711–720CrossRefPubMedGoogle Scholar
  12. Calvert AH, Ghokul S, Al Azraqui A et al (1999) Carboplatin and paclitaxel, alone and in combination: dose escalation, measurements of renal function, and role of the p53 tumor suppressor gene. Semin Oncol 26:676–684Google Scholar
  13. Cardenal F, Lopez-Cabrerizo MP, Anton A et al (1999) Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17:12–18PubMedGoogle Scholar
  14. Caro JJ, Salas M, Ward A et al (2000) Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91:2214–2221CrossRefGoogle Scholar
  15. Casas F, Viñolas N, Ferrer F et al (2003) Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 55:116–124CrossRefPubMedGoogle Scholar
  16. Choy H, Curran W, Scott CB et al (2002) Preliminary report of locally advanced multimodality protocol ( LAMP): ACR 247: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non-small lung cancer (LA:NSCLC). Proc Am Soc Clin Onc 21:291aGoogle Scholar
  17. Croizat H, Frindel E, Tubiana M (1976) Abscopal effect of irradiation on hematopoietic stem cells of shielded bone marrow. Role of migration. Int J Radiat Oncol Biol Phys 30:347–358Google Scholar
  18. De Campos E, Radford J, Steward W et al (1995) Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 13:1623–1631PubMedGoogle Scholar
  19. Dewys WD, Begg C, Lavin PT et al (1980)Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491–497PubMedGoogle Scholar
  20. Dillman RO, Seagren SL, Propert KJ et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small cell lung cancer. N Engl J Med 323:940–945PubMedGoogle Scholar
  21. Elderly Lung Cancer Vinorelbine Italian Study Group (ELVIS) (1999) Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. JNCI 91:66–72Google Scholar
  22. Ettinger DS (1988) The role of carboplatin in the treatment of small cell lung cancer. Oncology 12[Suppl 2]:36–43Google Scholar
  23. Fossella F, Pereira JR, Pawel JV et al (2003) Study of docetaxel plus platinum combinations v). Randomized, multinational, Phase III versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. JCO 21:3016–3024CrossRefGoogle Scholar
  24. Frasci G, Lorusso V, Panza N et al (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529–2536PubMedGoogle Scholar
  25. Fukuoka M, Furuse K, Saijo N et al (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. JNCI 83:885–891Google Scholar
  26. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692–2699PubMedGoogle Scholar
  27. Gandara DR, Edelman M, Lara P et al (2000) Evolution of combined modality therapy for stage III non-small cell lung cancer. Oncology 14:35–41Google Scholar
  28. Georgoulias V, Samonis G, Papadakis E et al (2001) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34:47–51CrossRefPubMedGoogle Scholar
  29. Gregor A, Drings P, Burghouts J et al (1997) Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol 15:2840–2849PubMedGoogle Scholar
  30. Gridelli C, Perrone F, Gallo C et al (2003) Chemotherapy for Elderly patients with advanced non-small-cell lung cancer: the multicenter Italian lung cancer in the elderly study (MILES) phase III randomized trial. JNCI 95:362–372PubMedGoogle Scholar
  31. Henke M, Guttenberg R, Barke A et al (1999) Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 50:185–190CrossRefPubMedGoogle Scholar
  32. Howard A, Pelc SR (1951) Nuclear incorporation of 32P as demonstrated by autoradiographs. Exp Cell Res 2:178–187CrossRefGoogle Scholar
  33. Huchet A, Belkacemi Y, Frick J et al (2003) Plasma Flt-3 ligand concentration correlated with radiation-induced bone marrow damage during local fractionared radiotherapy. Int J Radiat Oncol Biol Phys 57:508–515CrossRefPubMedGoogle Scholar
  34. Jeremic B, Acimovic L, Djuric L (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452–458PubMedGoogle Scholar
  35. Jeremic B, Shibamoto Y, Acimovic L et al (1997) Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol 15:893–900PubMedGoogle Scholar
  36. Kelly K, Crowley J, Bunn PA et al (2001) Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a southwest oncology group trial. J Clin Oncol 19:3210–3218PubMedGoogle Scholar
  37. Kerr DJ, Lewis C, O'Neil B et al (1990) The myelotoxicity of carboplatin is influenced by the time of its administration. Hematol Oncol 8:59–63PubMedGoogle Scholar
  38. Komaki R, Lee JS, Kaplan B et al (2002) Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage I–III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol 12:46–49CrossRefPubMedGoogle Scholar
  39. Kovacs C, Evans M, Hooker J et al (1988) Long-term consequences of chemotherapeutic agents on hematopoiesis: development of altered radiation tolerance. NCI Monogr (6):45–60PubMedGoogle Scholar
  40. Langer CJ, Manola J, Bernardo P et al (2002) Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer. Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. JNCI 94:173–181PubMedGoogle Scholar
  41. Langer CJ, Stephenson P, Schiller J et al (2003) ECOG 1599: randomized phase II study of paclitaxel/carboplatin vs cisplatin/gemcitabine in performance status (PS) 2 patients with treatment-naive advanced NSCLC. PASCO S18:052Google Scholar
  42. Le Chevalier T, Arraigada R, Quoix E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer. First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–423PubMedGoogle Scholar
  43. Lilenbaum RC, Herndon J, List M et al (2002) Single agent versus combination chemotherapy in advanced non-small-cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. Proc Am Soc Clin Oncol 21:1aGoogle Scholar
  44. Ludwig H, Fritz E, Kotzmann H et al (1990) Erythropoietin treatment in anemia associated with multiple myeloma. N Engl J Med 322:1693–1699PubMedGoogle Scholar
  45. Lujan AE, Mundt AJ, Yamada SD et al (2003) Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 57:515–521CrossRefGoogle Scholar
  46. Lyman SD, Seaberg M, Hanna R et al (1995) Plama/serum levels of Flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 86:4091–4096PubMedGoogle Scholar
  47. MacRae Shyr Y, Johnson D, Choy H (2002) Declining hemoglobin during chemoradio-therapy for locally advanced non-small cell lung cancer is significant. Radiother Oncol 64:37–40PubMedGoogle Scholar
  48. Miller CB, Jones RJ, Piantadosis S et al (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689–1692PubMedGoogle Scholar
  49. Murray N, Coy P, Pater JL et al (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11:336–344PubMedGoogle Scholar
  50. Ozer H, Armitage JO, Bennet CL et al (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18:3558–3585PubMedGoogle Scholar
  51. Pivot X, Guardiola E, Etienne M et al (2000) An analysis of potential factors allowing an individual prediction of cisplatin-induced anemia. Eur J Cancer 36:852–857CrossRefPubMedGoogle Scholar
  52. Ransom M, Davidson N, Nicolson M et al. (2000) Randomized trial of pladitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer: J Natl Cancer Invest 92:1074–1080Google Scholar
  53. Ratain MJ, Schilsky RL, Conley BA et al (1990) Pharmacodynamics in cancer therapy. J Clin Oncol 8:1739–1753PubMedGoogle Scholar
  54. Rizzo JD, Lichtin AE, Woolf SH et al (2002) Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 20:4083–4107PubMedGoogle Scholar
  55. Robnett TJ, Machtay M, Han S et al (2002) Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients. Cancer J 8:263–267PubMedGoogle Scholar
  56. Sause WT, Scott C, Taylor S et al (1995) Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresected non-small cell lung cancer. JNCI 87:198–205PubMedGoogle Scholar
  57. Schaake-Koning C, van der Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524–530PubMedGoogle Scholar
  58. Scagliotti GV, de Marinis F, Rinaldi M et al (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20:4285–4291CrossRefPubMedGoogle Scholar
  59. Schapira L, Antin JH, Ransil BJ et al (1990) Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76:2354–2359PubMedGoogle Scholar
  60. Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98CrossRefPubMedGoogle Scholar
  61. Schmidinger M, Budinsky AC, Wenzel C et al (2000) Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancers and non small cell lung cancer. Wien Klin Wochenschr 28:617–623Google Scholar
  62. Shepherd F, Abratt R, Anderson H (1997) Gemcitabine in the treatment of elderly patients with advanced NSCLC. Semin Oncol 24[Suppl 7]:50–55Google Scholar
  63. Souhami RL, Spiro SG, Rudd RM et al (1997) Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. JNCI 89:577–580CrossRefPubMedGoogle Scholar
  64. Sweeney CJ, Zhu J, Sandler AB et al (2001) Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594. A phase III trial in patients with metastatic non-small cell lung carcinoma. Cancer 92:2639–2647CrossRefPubMedGoogle Scholar
  65. Takada M, Fukuoka M, Kawahara M et al (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054–3060CrossRefPubMedGoogle Scholar
  66. Thatcher N (1996) Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicenter randomised trial. Medical research Working Party. Lancet 348:563–566CrossRefPubMedGoogle Scholar
  67. Thatcher N, de Campos ES, Bell DR et al (1999) Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Br J Cancer 80:396–402PubMedGoogle Scholar
  68. Tjan-Heijnen VC, Postmus PE, Ardizzoni A et al (2001) Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study. Ann Oncol 12:1359–1368CrossRefPubMedGoogle Scholar
  69. Trovo MG, Minatel E, Franchin G et al (1992) Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 254:11–15Google Scholar
  70. Tubiana M, Frindel E, Croizat H (1979) Effects of radiation on bone marrow. Pathol Biol 27:326–334PubMedGoogle Scholar
  71. Turrisi AT, Johnson DV, Comis RL (1993) Small-cell carcinoma of the lung. In: Jhon MJ (ed) Chemoradiation an integrated approach to cancer treatment. Lea and Febiger, Philadelphia, pp 347–360Google Scholar
  72. Turrisi AT, Kim K, Blum R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271CrossRefPubMedGoogle Scholar
  73. Vadhan-Raj S (2001) Recombinant human thrombopoietin in myelosuppressive chemotherapy. Oncology 15:35–38Google Scholar
  74. Verwey J, de Vries J, Pinedo HM (1987) Mitomicin C-induced renal toxicity, a dose-dependent side effect? Eur J Cancer Clin Oncol 10:263–265Google Scholar
  75. Vokes EE, Rendón JE, Crawford J et al (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20:4191–4198CrossRefPubMedGoogle Scholar
  76. Yuen AR, Zou G, Turrisi AT et al (2000) Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 89:1953–1960CrossRefPubMedGoogle Scholar
  77. Zaragoulidis K, Papagiannis A, Ziogas E et al (1997) Management of chemotherapy-related anaemia with low-dose recombinant human erythropoietin in patients with small cell lung cancer. Eur J Cancer 33:2428–2431CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Francesc Casas
    • 1
  • Núria Viñolas
    • 1
  1. 1.Radiation and Medical Oncology Departments (ICMHO)Hospital Clínic i UniversitariBarcelonaSpain

Personalised recommendations